Reference: Follitropin alfa + Zoladex

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Hypogonadism

Conditions

Hypogonadism

Trial Timeline

Jul 21, 2025 → Dec 23, 2025

NCT ID

NCT07097259

About Reference: Follitropin alfa + Zoladex

Reference: Follitropin alfa + Zoladex is a phase 1 stage product being developed by Merck for Hypogonadism. The current trial status is completed. This product is registered under clinical trial identifier NCT07097259. Target conditions include Hypogonadism.

What happened to similar drugs?

6 of 19 similar drugs in Hypogonadism were approved

Approved (6) Terminated (3) Active (12)

✅Topical Testosterone SolutionEli LillyApproved

✅AndroGel® + PlaceboAbbVieApproved

✅AndroGel 1.62%AbbVieApproved

✅Testosterone Undeconate (Nebido, BAY86-5037) + PlaceboBayerApproved

✅NEBIDO + PLACEBOBayerApproved

✅JatenzoICON plc.Approved

🔄Testosterone Solution + Placebo SolutionEli LillyPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07097259	Phase 1	Completed	Jul 21, 2025	Dec 23, 2025	Hypogonadism

Competing Products

20 competing products in Hypogonadism

See all competitors

Product	Company	Stage	Hype Score
Topical Testosterone Solution	Eli Lilly	Approved	43
Testosterone Solution + Placebo Solution	Eli Lilly	Phase 3	40
Testosterone MD-Lotion	Eli Lilly	Phase 2	35
Testosterone MD-Lotion	Eli Lilly	Phase 3	40
Testosterone MD-Lotion	Eli Lilly	Phase 3	40
Testosterone Gel 1.62% + Testosterone Gel 1.62%	AbbVie	Phase 1	29
ABT-SLV176	AbbVie	Phase 3	32
AndroGel® + Placebo	AbbVie	Approved	43
AndroGel 1.62%	AbbVie	Approved	43
Recombinant human luteinizing hormone (r-hLH) + Recombinant human follicle-stimulating hormone (r-hFSH) + Human chorionic gonadotropin (hCG)	Merck	Phase 3	40
Oral testosterone undecanoate (Andriol) + Placebo	Merck	Phase 2	35
Testosterone + Alendronate + Placebo Alendronate + Placebo Testosterone	Merck	Phase 2	27
Testosterone Enanthate + Finasteride	Merck	Phase 2	35
Testim 1% (testosterone gel) + Placebo	Merck	Phase 2	27
Investigational new drug company code: BGS649 + Placebo	Novartis	Phase 2	27
Test formulation + Reference formulation	Pfizer	Phase 1	29
Testosterone Product	Bayer	Pre-clinical	23
Testosterone undecanoate (TU) - NebidoTM	Bayer	Phase 3	37
Testosterone Undeconate (Nebido-R, BAY86-5037)	Bayer	Pre-clinical	23
Testosterone Undeconate (Nebido, BAY86-5037) + Placebo	Bayer	Approved	32